Skip to main content
Home
  • About Us
    • Our Credo
    • Board of Directors
      • Committees of Board
    • Management Council
    • Manufacturing
    • Quality
    • Code of Conduct
    • Our History - Cipla Archives
      • Scientist with a Heart- Dr. Y K Hamied
    • 90 years of caring for life
    • Legacy of Care | Comic Book
    • Milestones and Awards
  • Our Presence
    • Australia
    • Brazil
    • Europe
    • Germany
    • Ghana
    • Kenya
    • Malaysia
    • Morocco
    • Nepal
    • South Africa
    • Spain
    • Sri Lanka
    • Uganda
    • United Kingdom
    • USA
  • Our Offerings
    • Our Therapies
      • Respiratory
        • Asthma
        • Paediatric Asthma
        • COPD
        • Nebulization
      • HIV/AIDS
      • Oncology
      • Other Therapies
    • AMR
    • Cipla Generics
      • Products
        • Cipcal
        • Easylax
        • Easylax-L
    • OTC – Cipla Health
    • Cipla Diagnostics
    • API
    • Covid Care
  • Investors
    • Financials & Filings
      • Quarterly Results
      • Investor Presentation
      • Annual Reports
      • Scheme of Arrangement
    • Disclosure under regulation 46 of SEBI LODR
    • Corporate Governance
    • Cipla at a Glance
      • Board Of Directors
    • Investor Resources
    • Shareholding Pattern
    • Intimation to Stock Exchange
    • Unclaimed Data
    • Investor Contacts
    • Disclaimer
  • Sustainability
    • Championing Climate Positivity
    • Accelerated Community Well-being
      • Community Initiatives
      • Employee Initiatives
    • Raising the Bar on Governance
    • Enhancing Access and Affordability
    • ESG Profile
  • Careers
    • Life at Cipla
    • Business Functions
    • Diversity & Inclusion
    • Holistic Wellbeing
    • Cipla University
    • Join Us
  • Media Releases
  • Corporate Social Responsibility
    • Cipla Foundation
    • Cipla Palliative Care
      • Annual Update 2025
      • Annual Update 2023-24
    • CSR Policy
    • CSR Committee
    • Approved CSR Projects
      • 2025-26
      • 2024-25
      • 2023-24
      • 2022-23
      • 2021-22
  • Contact Us
  • Global
    • Brazil
    • Kenya
    • South Africa
    • Sri Lanka
    • United Kingdom
    • USA

Breadcrumb

  • Home
  • investors
  • investor resources

Investor Resources

Quick Explore

  • Corporate Governance
  • Shareholding Pattern
  • Investor contact
icon-pdf
Notice of 84th AGM and E-voting Information – Newspaper Publication
06th Aug 2020
icon-pdf
Notice of 84th Annual General Meeting of Cipla Limited
05th Aug 2020
icon-pdf
Notice of Book Closure – Newspaper Publication
03rd Aug 2020
icon-pdf
84th Annual General Meeting – Newspaper Publication
01st Aug 2020
icon-pdf
Revised Earnings Conference Call
29th Jul 2020
icon-pdf
Earnings Conference Call
28th Jul 2020
icon-pdf
Secretarial Compliance Report
27th Jul 2020
icon-pdf
Clarification on news item appearing in the “Newspaper-The Economic Times” dated July 23, 2020 captioned “Cipla all set to launch Favipiravir drug for treatment of COVID patients (Article).
26th Jul 2020
icon-pdf
Press Release – Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19
24th Jul 2020
icon-pdf
Shareholding Pattern as on 30th June 2020
22nd Jul 2020
  • +
 
BSE and NSE Quotes by TradingView

The displayed data is not in real time and may have streaming delays.

Corporate Information

  • About Us
  • Scientist with a Heart- Dr. Y K Hamied
  • 90 years of caring for life
  • Milestones and Awards

Our Presence

  • Our Presence
  • Australia
  • Brazil
  • Europe
  • Germany
  • Ghana
  • Kenya
  • Malaysia
  • Morocco
  • Nepal
  • South Africa
  • Spain
  • Sri Lanka
  • Uganda
  • United Kingdom
  • USA

Our Offerings

  • Our Offerings
  • Our Therapies
  • Respiratory
  • Asthma
  • COPD
  • Nebulization
  • Paediatric Asthma
  • HIV/AIDS
  • Oncology
  • Other Therapies
  • AMR
  • Cipla Generics
  • Products
  • Cipcal
  • Easylax
  • Easylax-L
  • OTC – Cipla Health
  • Cipla Diagnostics
  • API
  • Covid Care

Sustainability

  • Sustainability
  • Accelerated Community Well-being
  • Championing Climate Positivity
  • Community Initiatives
  • Employee Initiatives
  • Enhancing Access and Affordability
  • Raising the Bar on Governance
  • ESG Profile

Investor Information

  • Investors
  • Financials & Filings
  • Quarterly Results
  • Investor Presentation
  • Annual Reports
  • Scheme of Arrangement
  • Corporate Governance
  • Disclosure under regulation 46 of SEBI
  • Cipla At a Glance
  • Investor Resources
  • Shareholding Pattern
  • Intimation to stock Exchanges
  • Unclaimed Data
  • Investor Contact
  • Disclaimer

Media

  • Media Center
  • Media Releases

Career Sitemap

  • Careers
  • Life at Cipla
  • Business Functions
  • Diversity & Inclusion
  • Holistic Wellbeing
  • Cipla University
  • Join Us

Corporate Social Responsibility

  • CSR-Cipla Foundation
  • Cipla Palliative Care
  • Annual Update 2023-24
  • CSR Policy
  • CSR Committee
  • Approved CSR Projects
  • - 2024-25
  • - 2023-24
  • - 2022-23
  • - 2021-22

Quick Links - Footer

  • Privacy Policy
  • Disclaimer
  • Contact Us
  • Sitemap
  • Beware of Recruitment Fraud
  • Drug Safety Reporting

Chatbot API

  • Terms & Condition
  • Privacy Policy
  • Disclaimer
  • Terms of Use

Related Links

  • breathefree.com
  • ciplamed.com

© Copyright 2019 Cipla. All rights reserved

Digital Partner : Indus Net Technologies

  •  
  •  
  •  
  •  

Subscribe to Cipla Newsletter

  •  
  •  
  •  
  •  
  •  

Mobile Footer Menu

  • Remdesivir Supply Details - Maharashtra
  • Caution Notice - "Recruitment Fraud"
  • Contact Us
  • Disclaimer
  • Privacy Policy

© Copyright 2019 Cipla. All rights reserved

×

We use cookies on this site to enhance your user experience

By continuing to browse our website, you agree to the use of cookies. More info

Accept All Cookies
Reject Cookies
Manage Preferences

Cookie Preferences

×
Save Preferences